Raising capital: how UK biotechs can avoid the 'worst of both worlds'

The struggles and successes of UK biotechs in raising capital show the particular challenges of accessing funds on different sides of the Atlantic, as Chris Pettigrew of Novasecta explores in our expert view piece.

For biotechnology, the UK capital market is very much driven by its relationship with other international markets, most notably the USA and continental Europe.

The specific qualities of these larger markets have a substantial impact on the UK, creating a unique landscape of capital and subsequent innovation. This phenomenon is readily apparent in both early-stage and later-stage pre-initial public offering (IPO) biotech fundraising.